Navigation Links
Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/11/2010

BEDMINSTER, N.J., Nov. 11, 2010 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that Jerry Wisler, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at the St. Regis hotel in New York City on November 17, 2010 at  1:15pm Eastern time.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  The lead product candidate is Epanova, an Omega 3 fatty acid compound preparing to enter Phase III clinical development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL).  Future planned clinical trials for Epanova include patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.  Omthera holds worldwide rights to Epanova.   For more information, please visit www.omthera.com.Media ContactRx Communications Group, LLCEric GoldmanVice President, Public Relations917-322-2563egoldman@rxir.com
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 /PRNewswire-iReach/ -- Phoenix Houses of California ... organization, is hosting its tenth annual "Triumph For Teens" ... 6, 2013.  More than 300 people are expected to ... residential treatment centers, family therapy, and prevention programs of ... have positive influences on the health and welfare of our ...
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, ... and specialty products, announced today that Dr. Robert ... and Jason Napolitano , executive vice president ... Marcum MicroCap Conference, which is being held May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer").  On 20 May 2013, ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... Amgen (Nasdaq: AMGN ) today announced results ... treatment for advanced cancer patients with bone metastases in ... (zoledronic acid). These results underscore the efficacy profile of ... bone metastases from advanced breast cancer, as well as ...
... Dec. 10, 2010 Syndax Pharmaceuticals, Inc., a clinical-stage ... on entinostat, an orally bioavailable, highly selective, class I ... cancer. The data are being presented as oral poster ... 8 through December 12 in San Antonio Texas. ...
Cached Medicine Technology:Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 2Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 3Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 4Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 5Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 6Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 7Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 8Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 9Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 10Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 11Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 12Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS 13Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 2Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 3Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer 4
(Date:5/24/2013)... Compromise is often cited as crucial for relationships, ... sleep and comfort. However, many couples find themselves facing dilemmas ... this can cause added stress, lost sleep, and some resentment. ... common issues in their latest article on the subject. ... What to do When You Disagree on the Best Mattress ...
(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... the 2010 DePuy hip recall continue to move forward ... According to documents filed in California’s San Francisco ... been seeking an expedited trial of her DePuy hip ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. CGC11508806; ...
(Date:5/24/2013)... 24, 2013 KC and Monica Craichy, Founders ... for FreeRide836. Their oldest sons, Kyle and Austin Craichy, will ... family and several professional kiteboarders. , KC Craichy said he ... has miraculously come together such that virtually everyone who planned ... , 20 kite boarders will meet at Matheson Hammock Park ...
(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...
(Date:5/24/2013)... Teams of highly respected Alzheimer,s researchers failed to replicate ... of this brain disease when they were published last ... results, presented online Feb. 9, 2012, suggested that the ... buildup of beta amyloid plaques (Aβ) a pathological ... mice. According to the authors of the 2012 report, ...
Breaking Medicine News(10 mins):Health News:What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3
... Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates ... , NEW YORK, June 19, 2009 Forest Laboratories, ... from two global multi-center Phase III studies of ceftaroline for ... data in each of the pivotal trials (FOCUS I and ...
... Kenneth A. May, former CEO of FedEx Kinko,s, has been ... Dimes, it was announced today. , , "Ken May is ... Prematurity Campaign," said Dr. Jennifer L. Howse, President of the March ... work towards our goal of giving every baby a healthy start ...
... changes , FRIDAY, June 19 (HealthDay News) -- A key ... by British researchers, who suggest that their finding may lead ... King,s College London and Imperial College London helps explain why ... are remodeled and how these changes contribute to chronic asthma. ...
... The Center for Laser Surgery, Washington, DC has announced the ... recently FDA approved, is the first cosmetic neurotoxin available alongside ... The Center for Laser Surgery was ... Dysport. As Washington, DC, Maryland and Virginia,s largest and most ...
... , WASHINGTON, June 19 The Department of Veterans Affairs ... its award-winning health care system, is poised to welcome nearly ... the country by expanding access to health care enrollment for ... , , "This incremental approach to expanding enrollment ensures ...
... should be treated as a priority if offenders held in ... research from the University of Adelaide, Australia. Adelaide researchers ... health of young offenders undertaken in the USA, UK, Europe ... have been published in this month,s Australian Journal of ...
Cached Medicine News:Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 2Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 3Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 4Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 5Health News:Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative 2Health News:VA Reopening Health Care Enrollment to Thousands of Veterans 2Health News:Young offenders' health critical to rehabilitation 2Health News:Young offenders' health critical to rehabilitation 3
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....
... accelerators are true high-performance ... multileaf collimation and electronic ... enable you to perform ... IMRT treatments, as well ...
... Clinac EX accelerators ... with integrated Varian multileaf ... imaging systems which enable ... most advanced computer-driven IMRT ...
The Clinac C family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
Medicine Products: